Back to top
more

Ayala Pharmaceuticals, Inc. (ADXS)

(Delayed Data from OTC)

$0.26 USD

0.26
16,486

+0.01 (2.36%)

Updated May 31, 2024 12:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ADXS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Ayala Pharmaceuticals, Inc. [ADXS]

Reports for Purchase

Showing records 21 - 40 ( 96 total )

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

06/14/2017

Company Report

Pages: 6

ADXS-DUAL Heading Into Pivotal Study; Axal Nearing EMA Submission; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

04/20/2017

Industry Report

Pages: 13

The Power of One: The Future of Personalized Cancer Therapy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 50.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

03/13/2017

Company Report

Pages: 6

ADXS-NEO IND Accepted by the FDA; Multiple Clinical Milestones in 2017; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

02/28/2017

Daily Note

Pages: 4

Opportunistic Agreement With SELLAS to Generate a Potential Revenue Stream

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

01/17/2017

Company Report

Pages: 6

Second Phase 3 Study in Cervical Cancer to Start; Multiple Clinical Results in 2H17; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

11/16/2016

Daily Note

Pages: 6

Key Takeaways From the SITC Research Reception; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

10/25/2016

Daily Note

Pages: 4

Positive Update From GOG-0265 Bodes Well for AIM2CERV; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

10/25/2016

Company Report

Pages: 13

Provider: Zacks Investment Research

Analyst: ZENG G

Price: 24.95

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

08/25/2016

Company Report

Pages: 13

Provider: Zacks Investment Research

Analyst: ZENG G

Price: 24.95

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

08/05/2016

Daily Note

Pages: 4

Significant Corporate Collaboration Spurs I/O Group

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: GRISEWOOD S

Price: 10.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

08/03/2016

Daily Note

Pages: 5

Amgen Agreement Affirms the Value and Potential of Lm-LLO; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

06/29/2016

Daily Note

Pages: 6

Clinical Update at Investor Day Highlight AXAL Potential; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

06/09/2016

Company Report

Pages: 8

Promising Data Presented at ASCO; Updates at Upcoming R-D Day; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

06/06/2016

Company Report

Pages: 11

Provider: Zacks Investment Research

Analyst: ZENG G

Price: 24.95

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

05/17/2016

Daily Note

Pages: 5

Aduro?s Failure Does Not ECLIPSE Advaxis'' Lm-LLO Platform; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

04/21/2016

Daily Note

Pages: 7

Our Takeaways from the Advaxis AACR Research Reception; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

03/23/2016

Industry Report

Pages: 5

Aratana reported on Monday that the Center for Veterinary Medicine

Provider: DAWSON JAMES SECURITIES, INC.

Price: 10.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

03/23/2016

Daily Note

Pages: 5

A new era is underway in companion animal therapeutics and more specifically in the blending of companion animal, comparative biology/oncology and human health

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: GRISEWOOD S

Price: 10.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

03/08/2016

Company Report

Pages: 11

Provider: Zacks Investment Research

Analyst: ZENG G

Price: 24.95

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

03/02/2016

Company Report

Pages: 7

Biotech Sector Weakness Downplay 2016 Catalysts; New $23 Price Target; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party